Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832691 | 0.93 | LMNA (0.33) | — | |
| SCHEMBL7130222 | 0.93 | LMNA (0.33) | — | |
| SCHEMBL6142784 | 0.93 | LMNA (0.33) | — | |
| SCHEMBL22323586 | 0.91 | CYP2C19 (0.35) | — | |
| SCHEMBL22324095 | 0.91 | CYP2C19 (0.35) | — | |
| SCHEMBL6143371 | 0.87 | LMNA (0.31) | — | |
| SCHEMBL6040475 | 0.86 | CYP2C19 (0.33) | — | |
| SCHEMBL3189299 | 0.85 | — | — | |
| SCHEMBL3695305 | 0.79 | — | — | |
| SCHEMBL8566496 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204447-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS | NATIONAL SCIENCE FOUNDATION | 2022-06-30 | — | — | US | disclosed |
| WO-2020163295-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-2173714-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2010014516-A1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK & CO., INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009015166-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1056749-A1 | NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999041254-A1 | NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204447-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS | DHPS, PCBP1, PNKP | CYP1A2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.